Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zacks News
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -26.67% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Cytokinetics (CYTK) Climb 48% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 47.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Cytokinetics (CYTK)? Wall Street Analysts Think 37%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Cytokinetics (CYTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.
New Strong Sell Stocks for August 27th
by Zacks Equity Research
CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021
New Strong Sell Stocks for August 18th
by Zacks Equity Research
CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -32.31% and -49.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Surges 40.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Company News for Jul 20, 2021
by Zacks Equity Research
Companies in The News Are: CALM,FIVN,ZM,NGG,CYTK
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.86% and -16.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Cytokinetics (CYTK) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
by Zacks Equity Research
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.
Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 91.53% and 997.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen Down on Unsatisfactory Heart Failure Drug Study Results
by Zacks Equity Research
Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.
Cytokinetics (CYTK) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Cytokinetics (CYTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.
Earnings Preview: Cytokinetics (CYTK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -23.81% and -27.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.